MEDICAL DIRECTOR CLINICAL AFFAIRS,DEVELOPMENT GLOBAL DRUGS,BIOLOGICS,ONCOLOGY AUTOIMMUNE,ANTI-INFLAMMATORY

Medical Director with extensive successful e xperience in directing biotech drug and biologics development and m anaging CRO's. have directed non-clinical programs, Phase I , II, III, IV clinical trials, Biostatistics, Regulatory Affairs. Therapeut ic areas include Oncology, CNS, GI, Respiratory, HIV & Infectious Disea se, Immunology, Anti-Inflammatory, Endocrinology, Critical C are, Allergy. Twenty years oncology clinical development experience-Phase I, Phase II,Phase III,Phase IV clinical trials -Global experience. Translational Medicine experience includes preclinical studies and novel Proof of Concept Phase I & Phase II C linical Trials employing biomarkers, genomics, proteomics, metabolomics, novel patient selection criteria. Therapeut ic areas include inflammation, respiratory, oncology. Consul tant to major pharmaceutical companies and leading biotec h companies. Oncology experience includes translational medicine and clinical Development programs for major pharma and biotechs : Pfizer,Bayer,Merck,Astra Zeneca,Glaxo,Eli Lilly,Amgen, Smith Kline,multiple early stage biotechs.

PFIZER CENTRAL RESEARCH-9/06-CURRENT Consultant-Global Drugs & Biologics Developm ent Groton,CT and New York City 25-40 hours/week Immunology,Oncology,Hematology Multiple early stage biotechs-oncology,autoi mmune. BEARDSWORTH CONSULTING GROUP-4/03 -7/06

Medical Director Oncology & Immunology A Full Service CRO 70 Church Street Flemington, NJ 08822 Anti-Inflammatory Drugs and Biologics Develo pment Phase I,II and III programs in asthma, rheu matoid arthritis, inflammatory bowel disease, multiple sclero sis, allergy, sepsis. drugs and biologics include monoclonal anti bodies, integrin inhibitors, TNF inhibitors, p38 inhibitors, cytokine and interleukin inhibitors. Vaccine clinical research and d evelopment . * Charged with leading international clinical development Teams for oral dual integrin inhibitors for multiple sclerosis Asthma,rheumatoid arthritis,Crohn's Disease and IBD. Led Phase I,IIa and IIb clinical trials.Organized ScientificAdvisory Board of i nternational experts in each therapeutic area.Phase III trials now being enrolle d. Clients were major pharmaceutical companies.Led clinical development teams with up to 75 multiple disciplinary clinical development professionals. * Initiated and led clinical development teams in Phase II and Phase III clinica l trials for rheumatoid arthritis with anti CD20 monoclonal antibody.Phase III c linical trials are in progress. Clinical Oncology Drugs and Biologics Devel opment Beardsworth has designed, managed, monitored, produced accurate datasets, analyz ed, and reported on oncology Phase I, II, III, IIIb in thousands of patients enr olled in hundreds of investigative sites. Significant oncology programs have bee n performed for major pharmaceutical companies and leading biotechnology compani es. Solid tumors: brain, breast, esophagus, head and neck, lung, melanoma, ovary, prostate, renal cell. Hematologic mal ignancies: acute myelogenous leukemia, chronic lymphocytic leukemia, hair y cell leukemia, multiple myeloma, non-hodgkins lymphoma. Drugs and bi ologics have included: monoclonal antibodies, antisense, proteasome inhibitors, angiogenesis inhibitors, anti-metabolite, an d cytotoxics. * Charged with Phase I,Phase II and Phase III clinical development of Velcade fo r resistant/refractory multiple myeloma. Responsibilities included design of clinical trials,clinical operations,NDA subm ission which was approved by FDA.Led clinical and regulatory teams with up to 80 multiple disciplinary professionals.

GLYCOGENESYS,INC 2/1999-4/2003 Chief Medical Officer Oncology & Immunology 31 St James Boston,MA 02116 Responsible for preclinical and clinical de velopment of novel Anti-inflammatory drugs and biologics for r heumatoid arthritis, IBD,multiple sclerosis and asthma. Key responsibilities also include design of Phase I ,II & III oncology clinical trials for GCS-100 - a no vel therapeutic that induces programmed cell death by selectively depola rizing the mitochondria of cancer cells as well as mediating a Bcl-2 p athway induced apoptosis of cancer cells. Responsible for establishi ng successful strategy for drug development of GCS-100 and all submissions and interactions with the FDA. Key role in successful joint vent ure funding with a major pharmaceutical company. Entrepreneuri al spirit, excellent communication skills, people management and project management. Responsible for clinical operations.. * Charged with preclinical and clinical development of a first In class novel galectin 3 inhibitor in oncology and immunology. Multiple Phase I and Phase II clinical trials with KOLs including Prostate cancer,colorectal cancer and pancreatic cancer. Created Phase III clini cal programs for multiple indications including prostate cancer,colorectal cance r,pancreatic cancer and breast cancer.Led clinical development teams with up to 70 multidisciplinary professionals. * Initiated preclinical and clinical development of novel galectin 3 inhibitor in auto immune disease including rheumatoid arthritis and asthma. * Discovered new clinical indication for novel galectin 3 inhibitor-cirrhosis of the liver.Organized world class development team and KOLs.Clinical development in progress. * Leadership role in all interactions with FDA. * Leadership role in raising over 25 million USD from private investors * Leadership role in establishing 50 million USD Joint Venture with the Elan Cor poration

SPRINGGATE ASSOCIATES 1998-Present President and Medical Director Oncology & I mmunology 1320 Little Meadow Road Guilford, CT 06437

Consultants to the pharmaceutical and biotechnology industry on medical issues, design of clinical trials, United States and international regulatory issues, pr oduct licensing, product development, pharmacovigilance. Oncology drugs and biologics development. Nonclinical safety and efficacy progra ms. Design and manage Phase I-Phase IV clinical trials for pancreatic, colorect al, prostate, breast, lung malignancies. Cytotoxic drugs and moleculary targeted oncology drugs including angiogenesis inhibitors, Receptor tyrosine kinase inhibitors, apoptosis inducers, inhibitors of metastasi s, Pharmacogenomics and proteomics. Gene therapy. Excellent FDA contacts. Medical Safety & Pharmacovigilance: Monitor and provide medical evaluation for a dverse events. Write safety expert reports and overall safety evaluation for aggregate safety reports. Make recommendations for labeling changes. Review documents relative to safety oversight. Familiar with regulatory guidelines and references. Experienced in post marketing pharmacovigilance. Deals with safety related issues using Critical medical and regulatory analytical strategies to develop optimal solutions. International Regulatory Affairs: Responsible for regulatory submissions in the U.S., Europe and Japan. Drugs, Biologics and Devices. Clinical Pharmacology: Design and execute Phase I, Phase II and Phase III clinic al trials for CNS therapeutics, infectious diseases including HIV, cardiovascula r, endocrinology, oncology, rheumatology. Extensive experience in pharmacokinetics. Quality Assurance: QA consulting responsible for compliance with Good Clinical P ractices, Good Manufacturing Practices and Good Laboratory Practices. Marketing: Design and execute Phase IV clinical trials for national and internat ional product launches for drugs, devices and biologics.

UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE Founder-Medical Director Oncology & Immunology Clinical Research Center New Britain General Hospital Affiliated-University of Connecticut School of Medicine 100 Grand Street New Britain, CT 06050 October 1995 - January 1998 Clinical Trials: Professional responsibilities include medical, scientific, reg ulatory and business direction of all Phase I, Phase II, Phase III and Phase IV clinical trials at New Britain General Hospital, a 350 bed acute care hospital w ith over 250 physicians on the Medical Staff. The Hospital is a major teaching hospital affiliated with the University of Connecticut School of Medicine. The Clinical Research Center, at the present time, is responsible for a total of ove r 100 state of the art clinical trials in Oncology, Cardiology, Neurology, Endoc rinology, Infectious Diseases, OB/GYN, Pediatrics, Psychiatry, Nuclear Medicine and Radiology. Clinical Pharmacology: Design and execute Phase I clinical trials for infectious diseases, cardiovascular, endocrinology, oncology, pulmonary medicine, psychiat

ry and neurology. International Regulatory Affairs: Responsible for regulatory in the U.S., Europe and Japan. Drugs, Biologics and Devices. submissions

Quality Assurance: Managed QA group responsible for compliance with Good Clinica l Practices, Good Manufacturing Practices and Good Laboratory Practices. Corporate Partnering: Structuring and negotiating domestic and international str ategic alliances. Research and development agreements. Product license agreeme nts. Distribution agreements. Separate entity joint ventures. Marketing: Design and execute Phase III and Phase IV clinical trials for nation al and international product launches for drugs, devices and biologies.

NATIONAL MEDICAL RESEARCH CORPORATION Vice President Clinical and Regulatory Affairs 25 Main Street Hartford, CT 06106 April 1994 - September 1995 Full service CRO where I had 125 muldiscipli nary clinical development Professionals reporting to me including MDs ,Ph.D.s,CRAs. Professional responsibilities include design and execution of Phase I, Phase II, Phase III and Phase IV Clinical Trials. Provide regulatory consultation to lea ding biotechnology companies and major pharmaceutical companies. Consultation i ncludes quality of life and pharmaco-economic evaluation * Charged with clinical development of novel biologic for multiple sclerosis inc luding Phase II and Phase III trials.Leadership Responsibility for NDA submission which was approved by the FDA for Copaxone.Organized panel of KOLs. Projects included: International Regulatory Affairs: Responsible for regulatory submissions in the U.S., Europe and Japan. Drugs, biologics and devices. Quality Assurance: Managed QA group responsible for compliance with Good Clinica l Practices, Good Manufacturing Practices and Good Laboratory Practices. Central Nervous System: Design and execute Phase I, Phase II and Phase III clini cal trials for Alzheimer's disease, Parkinson's disease, stroke, dementia, depre ssion, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. Clinical trials in cluded significant populations of elderly patients. Gerontology: Design Phase 1, Phase II and Phase III clinical trials with signif icant population of elderly patients. Oncology: Design Phase I, Phase II and Phase III Clinical trials for breast, ova rian, colon, prostate, as well as melanoma and Kaposi's sarcoma. Gene Therapy: Design Phase I and Phase II clinical trials for gene therapy of human cancers employing modifications of tumors, antisense oligodeoxy nucleotides, suicide genes, stem cell modification and lymphocyte modification. Rheumatology: Phase III clinical programs for rheumatoid arthritis and osteoart hritis.

Infectious Disease: AIDS - Design and execution of Phase I Trial to evaluate nov el HIV-1 protease inhibitor. Influenza A and B - Design and execute Phase II Tr ial to evaluate efficacy and safety of novel inhaled and intranasal therapeutic for treatment and prevention of influenza. Septic Shock - Design and execution of Phase II and Phase III studies to evaluat e novel tumor necrosis factor receptor blockers. Surgical Infections - Design and execute Phase III clinical trials for complicat ed intra-abdominal infections, prophylaxis of colo-rectal surgeries and pelvic i nfections with a novel antibiotic. Projects also included Phase I, II and III clinical trials for asthma.

GENZYME Clinical Research Group-Full Service CRO Vice President of Product Development and Medical Director London,La Jolla,Boston and New Jersey November 1989 - March 1994 All business units reported to me including: Regulatory Affairs; Biostatistics; New Product Development; Clinical Trials Design and Monitoring - Phase I, Phase II, Phase III, and Phase IV; Medical Writing, finance and marketing. Provide consultation to leading biotechnology companies and the major pharmaceutical companies. Projects included: International Regulatory Affairs: Responsible for regulatory submission in the U .S., Europe and Japan. Central Nervous System: Design and execute Phase I, Phase II and Phase III clini cal trials for Alzheimer's disease, Parkinson's disease, stroke, dementia, depre ssion, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. Clinical trials in cluded significant populations of elderly patients. Gerontology: Design Phase 1, Phase II and Phase III clinical trials with signif icant population of elderly patients. Oncology: In preparation for filing Product License applications, design Clinic al Development Programs for ex vivo therapies with monospecific and bispecific monoclonal antibodies. Experience in designing clinical developm ent programs involving autologous and allogenic bone marrow transplantation with both positive selection therapeutic strategies (CD34+) and negative selection. (Purging with monoclonal antibodies specific for tumor cells.) Hematology: In preparation for filing appropriate Product License Applications, design clinical development programs for antithrombin III and Von Willebrands f actor. Infectious Disease: Design Clinical Development Programs and evaluate novel ther apies for AIDS, Septic Shock and Lyme Disease. Rheumatology: Design and execute Clinical Development Program for osteoarthritis

, rheumatoid arthritis and systemic Lupus Erythematosus. Blood Bank: Design and execute a Clinical Development Program for novel blood su bstitute and for a novel family of solutions for cryopreservation of blood compo nents. Immunotherapy: Evaluate a novel autologous vaccine for human colorectal carcinom a. Evaluate novel therapeutic strategies for Interleukins, Growth Factors and C ell Adhesion Molecules. SCICOR-COVANCE CENTRAL LABS Vice President of Professional Services 2643 Rand Road Indianapolis, IN 46241 July 1988 - October 1989 Accepted Genzyme Position when Corning bought Scicor. Corporate Objectives:Scicor does clinical testing for the forty major pharmaceut ical companies in collaboration with over two thousand physician-investigator si tes at major medical centers, universities and clinics.

Responsibilities: Medical, scientific and administrative direction of all sections of the Clinical Laboratory including Immunology, Hematology, Microbiology, Urinalysis and Radio immunoassay. The Clinical Laboratory was staffed by 80 health care professional s. Medical, scientific and administrative direction of the Technical Administration Department. This department was responsible for Clinical Project Design, estab lishing disease specific reference ranges for all clinical tests, statistical an alysis of test results and the integrity of the medical and scientific database. Medical and scientific consultant to the forty major pharmaceutical companies ad vising on design of clinical trials, selection of clinical tests, statistical an alysis of clinical results. Scicor is now doing clinical testing for over three hundred clinical trials including Phase I, Phase II, Phase III and Phase IV. The clinical trials include the evaluation of new therapeutics in the discipline s of Infectious Diseases, Virology, AIDS, Rheumatology, Diabetes, Hyperlipidemia , Hematology, Cardiovascular and Neurology. Accomplishments: Profits increased over five hundred percent (500%) in the past twelve months as business volume increased over three hundred percent (300%). Successfully managed both the Clinical Laboratory and the Department of Technica l Administration during three hundred per-cent (300%) growth. Designed and impl emented management structure for all laboratory sections. Recruited key health care professionals, formulated the budget for the Clinical Laboratory and Techni cal Administration on a quarterly basis owing to explosive growth rate. Managed New Test Development Program. Ensured compliance with all federal, stat e and local regulations. Had the leadership responsibility for preparing the Cl inical Laboratory for inspections by the college of American Pathology, CLIA and the FDA. Inspections were also conducted by the pharmaceutical companies. Und er my direction, all inspections went well and let to accreditation by all appro priate agencies.

OCHSNER CLINIC 7/85-6/88 Medical Director and Attending Physician Clinical Immunology Laboratories New Orleans,La * Rheumatology: Responsible for all clinical immunology profiles. Clinical resea rch to improve treatment of patients with severe rheumatoid arthritis and SLE by immune monitoring and monoclonal antibodies. AIDS: Responsible for stateof-the-art lymphocyte subset analysis for all AIDS patients at Ochsner. Oncology: Responsible for immunophenotyping all leukemias and lymphomas. Clini cal research with B cell activation monoclonals. DNA laser flow cytometry to mo nitor patients with bladder carcinoma, breast carcinoma, colon carcinoma and pro state carcinoma. Transplantation: Clinical research to develop state of the art immune monitorin g with monoclonal antibodies and laser flow cytometry for heart, liver and renal transplantation. Immunohematology: Immunoelectrophoresis workups. Immunofixation. Share responsi bility for HLA, Serology Laboratories and Blood Bank Hemotherapy including thera peutic aphaeresis.

Assistant Professor, Department of Microbiology and Immunology Tulane Medical Center New Orleans, LA 1976 - 1981 NIH and American Cancer Society Grants. Honors for excellence in teaching. Medical and scientific responsibility in Infectious Diseases and Virology.

EDUCATION AND Immunohematology Post Graduate Fellow July 1984 - June 1985 TRAINING Tulane Medical Center, New Orleans, Louisiana Resident in Clinical Pathology July 1983 - June 1984 Tulane Medical Center, New Orleans, Louisiana M.D. - M.D., Ph.D. Program June 1981 - May 1983 University of Miami School of Medicine, Miami, Florida Visiting Scientist and Postdoctoral Fellow

Fox Chase Center for Cancer and Medical Sciences University of Pennsylvania School of Medicine Philadelphia, PA 1971 - 1975 Clinical Research in oncogenic tumor viruses and carcinogenesis. Fellow of Leukemia Society of America Ph.D. Biochemistry September 1968 - May 1972 Boston College, Boston, Massachusetts National Science Foundation Predoctoral Fellow A.B. Biology September 1964 - August 1967 Boston University, Boston Massachusetts CERTIFICATION: Board Certified in Clinical Pathology, American Board of Patholog y, 1989 LICENSURE: Diplomate, National Board of Medical Examiners, July 1, 1984 Connecticut Medical Licensure, 1994

MEMBERSHIPS: Regulatory Affairs Professional Society Connecticut State Medical Society New Haven County Medical Association American Academy of Pharmaceutical Physicians American College of Physician Executives

SELECTED PUBLICATIONS AND ABSTRACTS 1. Springgate, C.F., Cartwright, T, .Belt, R., Redfern, C., Stuart, K. (2001)P hase II Study of GBC-590 in Patients with Relapsing or Refractory Colorectal Can cer Abstract. American Society of Clinical Oncology 2. Springgate, C.F. (1993) Prognostic Quantitative Pathologic Features in Ovari an Tumors and Adoptive Immunotherapy, Proceedings of the European Multicenter Ov arian Tumor Symposium, Invited Address. 3. Garner, R.J. Springgate, C.F. and Hoyt, T. (1989) Immune Monitoring of Blood in Heart Transplant Recipients: Application of Flow Cytometry, Seminars in Dia gnostic Pathology, 6, 83. 4. Springgate, C., Hussey, J. and Hoyt, D. (1988) Immune Monitoring Transplant Patients with Monoclonal Antibodies and Flow Cytometry, American Society for His tocompatibility and Immunogenetics, Invited Review. 5. Tseng, C.K., Springgate, C. et al (1988) Identification of a Novel Human B C ell Activation Antigen Involved in B Cell Growth Factor Dependent Proliferation, J.of Immunology, 140:2305. 6. Springgate, C. et al (1988) A Unique Lymphocyte Subset is Significantly Incr eased in Active Rheumatoid Arthritis but not in Polymyalgia Rheumatica, Abstract , American Rheumatism Association Meeting. 7. Springgate, C. et al (1988) Increased Helper Inducer T Cells in Polymyalgia

Rheumatica, Abstract, American Rheumatism Association Meeting. 8. Rosenberg, S., Blaiss, M. and Springgate, C. (1988) Emerging Therapies for A utoimmune Disease such as Systemic Lupus Erythematosus, Modern Medicine, 56: 4447. 9. Rosenberg, S., Blaiss, M. and Springgate, C. (1988) New Therapies for Diabet es Mellitus, Modern Medicine, 56:42-45. 10. Blaiss, M. and Springgate, C. (1988) Human Immune System Response to Allerg ens, Modern Medicine, 56:52-55. 11. Tseng, C., Springgate, C. et al (1987) Development and Characterization of a Human B Cell that Responds to B Cell Growth Factor but not Interleukin II, J.o f Immunology, 138: 2552. 13. Springgate, C., Flaum, M. and Cooper, E. (1987) The Therapeutic Potential o f the Interleukins, Modern Medicine, 55:44-46. 14. Springgate, C. Flaum, M. and Cooper, E. (1987) The Promise of Interferon i n the Treatment of Common Diseases, Modern Medicine, 55:44-46. 15. Cooper, E., Flaum, M, and Springgate, C. (1987) The Functions of T Cells i n Managing Arthritis, Allergens and Infections, Modern Medicine, 55:24-26. 16. Cooper, E., Flaum, M. and Springgate, C. (1987) Macrophages: Controllers o f the Human Immune System, Modern Medicine, 55:40-43.